ENTXEntera Bio Ltd

DELL, CAT and AMKR led standout gains as Zacks highlighted top-performing portfolios amid volatile markets and inflation worries.

Entera said that the FDA backed its plan for a single large late-stage clinical trial of its experimental once-daily pill, EB613, for postmenopausal women with osteoporosis.

Entera Bio (NASDAQ:ENTX) will be releasing its Q1 2026 earnings after the market closes on Friday, May 8. (View Earnings Report at...

Entera Bio (ENTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Entera Bio Ltd. (NASDAQ:ENTX - Free Report) - Analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Entera Bio in a research report issued to clients and investors on Monday, April 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings of ($0...

HC Wainwright lowered their price objective on shares of Entera Bio from $10.00 to $9.00 and set a "buy" rating on the stock in a research note on Monday...

Entera Bio (NASDAQ:ENTX) executives and physician panelists used a roundtable discussion to highlight what they described as persistent gaps in osteoporosis care and the potential role for the...

Entera Bio Ltd. (NASDAQ:ENTX - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 175,306 shares, a growth of 27.2% from the March 15th total of 137,789 shares. Currently, 0.4% of the shares of the...

Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners...